Bausch + Lomb Launches Pharmaceuticals Business in India

Thu Jun 30, 2011 7:42am EDT

* Reuters is not responsible for the content in this press release.

Bausch + Lomb, the global eye health company, today announced plans to
launch a pharmaceutical business in India through a strategic agreement
with Micro Labs, a leading provider of quality healthcare products. The
partnership will provide Bausch + Lomb with high-quality manufacturing
capabilities in the region that will speed the introduction of new
prescription and over-the-counter medicines targeted at a wide range of
eye diseases.

    Through the agreement with Micro Labs, Bausch + Lomb aims to capture part
of the rapidly expanding ophthalmic pharmaceuticals market in India which
is expected to reach US$300 million by 2015. In addition to gaining
access to world class manufacturing capabilities, Bausch + Lomb will
establish dedicated sales and marketing teams, and deliver practitioner
and patient education programs designed to improve the quality of, and
access to, eye care. 

    "With as many as 76% of patients suffering from eye disease in India
going untreated, Bausch + Lomb believes this is a critical time to enter
the market with medicines and education designed to improve patient
outcomes and overall quality of life," said Mr. Dan Wechsler, corporate
vice president and global president, Bausch + Lomb Pharmaceuticals.
"Today ophthalmic pharmaceuticals represent the fastest-growing segment
of our business globally, and our collaboration with Micro Labs will
enable us to enter one of the world's most vibrant yet underserved
markets in the world with high-quality and dependable products that may
help people see and live better."

    The companies will introduce up to six new pharmaceuticals eye drops
including Moxisurge(TM), Aquasurge(TM), Aquasurge Max(TM), Bromvue(TM),
Ketovue(TM) and Moxisurge-KT(TM). Furthermore, the companies have also
agreed to explore other areas of possible collaboration including: 

--  Sourcing of Ophthalmic Solution products from Micro Labs to be
    marketed and sold by Bausch + Lomb in India and other markets in Asia
--  Collaboration between the companies with respect to manufacturing
    technology for the production of eye drops.
--  Joint research & development of Ophthalmic Pharmaceutical products
    specifically for emerging markets.


"It gives us immense pleasure to partner with Bausch + Lomb, the
most powerful brand in eye health as they enter into the Pharmaceutical
segment in India," said Mr. Anand Surana, director, Micro Labs, India.
"Our collaboration demonstrates that pharmaceutical manufacturing in
India has come of age and our products meet the most stringent global
quality standards."

    Bausch + Lomb began commercial operations in India in 1992 with its
contact lens and solutions business before expanding into eye-related
surgery products in 1996. Today Bausch + Lomb is the market leader for
lenses and solutions in India and one of the fastest growing
multinational corporations in Surgical Ophthalmology in the region. 

    "Bausch + Lomb is committed to improving the quality of eye care in
India, and to helping doctors grow their practices and expand the range
of offerings they provide," said Harish Natarajan, managing director,
Bausch + Lomb India. "Our collaboration with Micro Labs will help us do
both quickly and with quality." 

    About Bausch + Lomb
 Bausch + Lomb is one of the best-known and most
respected healthcare companies in the world. Its core businesses include
contact lenses and lens care products, ophthalmic surgical devices and
instruments, and ophthalmic pharmaceuticals. Founded in 1853, the company
is headquartered in Rochester, N.Y., and employs more than 10,000 people
worldwide. Its products are available in more than 100 countries. More
information is available at 

    About Micro Labs Limited 
 Micro Labs Limited was established in the year
1973, with an objective of providing quality healthcare products at an
affordable cost. It has a strong presence in the domestic market in
Cardiology, Diabetology, Neuropsychiatry, Dermatology, Ophthalmology,
Antimicrobial Therapy and pain management. Micro Labs has recently
entered the Nephrology segment. Micro Labs has four overseas offices, and
has invested in creating five subsidiaries in the International markets
(UK, Philippines, Nigeria, South Africa & Mexico). 

    The group has presence in over 60 countries, exporting all major dosages
in every therapeutic segment. Being one of the leading Indian healthcare
providers in India, Micro Labs aims to be a prominent pharmaceutical
player in both regulated and non-regulated markets across the globe. The
R & D team is comprised of 200 scientists, pharmacists, analysts,
chemists and microbiologists engaged in product & analytical development.
R&D centre is an integrated set up with three research centres. 

    Moxisurge(TM), Aquasurge(TM), Aquasurge Max(TM), Bromvue(TM), Ketovue(TM)
and Moxisurge-KT(TM) are registered trademarks of Bausch & Lomb, Inc. 


News Media Contacts: 
Elizabeth Harness Murphy
Bausch + Lomb
+1 (585) 338-8528 

Melanie Nadeau Backs
Weber Shandwick on behalf of Bausch + Lomb
+1 (212) 445-8256 

Copyright 2011, Market Wire, All rights reserved.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.